Correlation Between POINT Biopharma and Molecular Partners

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both POINT Biopharma and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining POINT Biopharma and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between POINT Biopharma Global and Molecular Partners AG, you can compare the effects of market volatilities on POINT Biopharma and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in POINT Biopharma with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of POINT Biopharma and Molecular Partners.

Diversification Opportunities for POINT Biopharma and Molecular Partners

0.01
  Correlation Coefficient

Significant diversification

The 3 months correlation between POINT and Molecular is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding POINT Biopharma Global and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and POINT Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on POINT Biopharma Global are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of POINT Biopharma i.e., POINT Biopharma and Molecular Partners go up and down completely randomly.

Pair Corralation between POINT Biopharma and Molecular Partners

If you would invest  579.00  in Molecular Partners AG on September 5, 2024 and sell it today you would lose (28.00) from holding Molecular Partners AG or give up 4.84% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy1.56%
ValuesDaily Returns

POINT Biopharma Global  vs.  Molecular Partners AG

 Performance 
       Timeline  
POINT Biopharma Global 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days POINT Biopharma Global has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, POINT Biopharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Molecular Partners 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners may actually be approaching a critical reversion point that can send shares even higher in January 2025.

POINT Biopharma and Molecular Partners Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with POINT Biopharma and Molecular Partners

The main advantage of trading using opposite POINT Biopharma and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if POINT Biopharma position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.
The idea behind POINT Biopharma Global and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance